<DOC>
	<DOCNO>NCT00003847</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy treatment patient recurrent small cell lung cancer follow treatment .</brief_summary>
	<brief_title>VX-710 , Doxorubicin , Vincristine Treatment Patients With Recurrent Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Established safety VX-710 combination doxorubicin vincristine treatment patient recurrent small cell lung cancer . II . Characterized plasma pharmacokinetics regimen patient . III . Established ability regimen improve response rate chemotherapy patient relapse front-line therapy . IV . Evaluated multidrug resistance profile patient follow treatment regimen . OUTLINE : This multicenter study . Stage I : Patients receive VX-710 IV 72 hour , follow doxorubicin IV vincristine IV four hour initial VX-710 . Vincristine administer half dose first 3-6 patient . If 1 6 patient experience dose limit toxicity half dose cohort , 3 additional patient receive full dose vincristine . The maximum tolerate dose define dose precede 2 6 patient experience dose limiting toxicity . Stage II : Patients receive VX-710 IV 72 hour , follow doxorubicin IV full dose vincristine IV four hour initial VX-710 . Treatment continue 6 course every 3 week absence disease progression unacceptable toxicity . Patients follow every 3 month 1 year . PROJECTED ACCRUAL : A minimum 35 maximum 92 patient accrue study .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm oat cell intermediate type small cell lung cancer Patients must receive prior therapy , follow : Documented disease progression ( new lesion increase lesion size ) front line therapy No 1 prior chemotherapy regimen Complete partial response initial chemotherapy ( must last 60 day end therapy relapse occur ) Bidimensionally measurable disease At least one lesion outside irradiation field Pleural effusion measurable No brain bone metastases measurable site No uncontrolled brain CNS metastasis ( surgical excision and/or radiotherapy ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : Absolute neutrophil count least 1,500/mm3 Platelet count least 100,000/mm3 Hepatic : AST great 2 time upper limit normal Bilirubin great 1.5 mg/dL Renal : Creatinine le 1.3 mg/dL OR Creatinine clearance great 60 mL/min Cardiovascular : Cardiac ejection fraction great 45 % MUGA echocardiogram No uncontrolled ventricular arrhythmia Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No senile dementia psychiatric disorder Not concurrent serious infection No major seizure disorder No grade 3 neuropathy No spinal cord compression No concurrent unstable medical condition No prior malignancy within past 5 year , except : Adequately treat basal squamous cell skin cancer Any carcinoma situ PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics No prior doxorubicin vincristine first line treatment small cell lung cancer Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy great 50 % bone marrow At least 30 day since prior radiotherapy Surgery : Not specify Other : No concurrent experimental drug anticancer therapy Concurrent medication chronic medical condition allow ( e.g. , hypertension ) No concurrent cimetidine , phenothiazine , phenobarbital , carbamazepine , troleandomycin , sulfinpyrazone , rifampin , Dilantin , cyclosporineA ( Pgp inhibitor )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>recurrent small cell lung cancer</keyword>
	<keyword>intermediate type small cell lung cancer</keyword>
</DOC>